The Wall Street Journal, April 25

AstraZeneca posted increased first-quarter core earnings per share and sales that beat forecasts. The Anglo-Swedish pharmaceutical giant said Thursday that its core earnings per share increased to $2.06 from $1.92 the prior-year period. At 0910 GMT, Shares of AstraZeneca traded 5.2% higher at 11,940 pence. The stock was up 13% year to date but down 2.9% on year. Total revenue rose 19% to $12.68 billion boosted by product sales and continued growth in alliance revenue from partnered medicines which could offset waning demand for its Covid-19 products.

https://www.wsj.com/business/retail/astrazeneca-earnings-sales-rise-beat-forecasts-888ba507